Home > Insider Trading > Filing (0001209191-23-059431)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1584759	A. Richard Heyman	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-19	255	$13.00	149,565	No	4	S	Direct
Common Stock	Disposition	2023-12-20	2,110	$13.02	147,455	No	4	S	Direct
Common Stock	Disposition	2023-12-20	1,915	$13.02	29,257	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	37,407	Indirect	See footnote

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023.
This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.